CClinicalTrials.gg
CompletedNCT01178515Updated Jun 27, 2011

Low Fat Milk Intake and Cardio Vascular Risk (CVR) Indicators in Children

A Phase 4 interventional study of Modification of the content of fat in milk and Modification of the content of cows milk in Cardiovascular Diseases, sponsored by Instituto Nacional de Salud Publica, Mexico. Completed at 1 site in Mexico. Open to participants aged 6 Years to 13 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-06-27.

Sponsored by Instituto Nacional de Salud Publica, Mexico · Phase 4, Interventional, and Prevention

Phase
Phase 4
Study type
Interventional
Enrollment
650
Allocation
Randomized
Ages
6 Years to 13 Years
Sex
All
01

Study summary

Substituting whole milk intake for defatted milk will improve indicators of cardiovascular risk, i.e. total cholesterol, triglycerides, Low Density Lipoprotein (LDL) and High Density Lipoprotein (HDL)cholesterol, apolipoproteins: ApoB100, Lp(a) and ApoA in a sample of Mexican children 6-13 years of age.

Read the detailed description

Double blind trial in 600 children 6-13 years of age residing in 12 boarding schools. Schools will be randomized to distribute three types of milk namely: full fat milk (3% fat), partially defatted milk (2% fat) or defatted milk (1% fat) for 90 days of effective exposure (4 months total duration). Subjects will receive 400 mL of the corresponding milk every day (200 mL breakfast and 200 mL night meal) from Monday through Friday. During week ends they will eat a freely chosen diet at home. Milk intake will be measured every day. Diet by 24 h-recall. will be evaluated every month. Blood samples will be obtained at the beginning and at the end of the intervention.

02

Conditions studied

  • Cardiovascular Diseases

Keywords

  • epidemiological risk
  • diet
  • fat intake
03

In context

Cardiovascular Diseases

4,904 studies on the registry are indexed under Cardiovascular Diseases; 919 are open to participants now.

This study's enrollment of 650 is above the median of 100 across 2,738 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Instituto Nacional de Salud Publica, Mexico is the lead sponsor of 30 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 13 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Attending selected boarding schools

Exclusion criteria

Exclusion Criteria:

  • No lactose intolerance
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
650 participants (actual)

Study arms

  • Sham comparator
    Full fat milk

    Full fat milk contain 3% fat

    Other: Modification of the content of fat in milk

  • Experimental
    Partially defatted milk

    Partially defatted milk contains 2% of fat

    Other: Modification of the content of cows milk

  • Experimental
    Defatted milk

    Defatted milk contains 1% fat

    Other: Modification of the fat content of cows´ milk

Interventions

  • OtherModification of the content of fat in milk

    Comparison of three levels of fat content in cow´s milk

    Also known as: Liconsa milk

  • OtherModification of the content of cows milk

    Comparison of three levels of fat content in cows' milk

    Also known as: Liconsa low fat milk

  • OtherModification of the fat content of cows´ milk

    Comparison of three levels of fat content in cow´milk

    Also known as: Liconsa defatted milk

06

What researchers measure

Primary outcomes

  1. Cardiovascular risk indicators

    Cardiovascular risk is indicated by several determinations of blood fats namely: Total cholesterol, triglicerides, Low-density lipoprotein (LDL) and High density lipoprotein (HDL) cholesterol, lipoproteins: Apo a1,Apo B100 and Lp(a)

    Time frame: 4 months

07

Study locations

1 site
  • Comisíon para el Desarrollo de Pueblos Indigenas
    Pachuca, Hidalgo, Mexico
08

References and documents

Publications

  • Stevens G, Dias RH, Thomas KJ, Rivera JA, Carvalho N, Barquera S, Hill K, Ezzati M. Characterizing the epidemiological transition in Mexico: national and subnational burden of diseases, injuries, and risk factors. PLoS Med. 2008 Jun 17;5(6):e125. doi: 10.1371/journal.pmed.0050125. PubMed 18563960 ↗
  • Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998 Jun 4;338(23):1650-6. doi: 10.1056/NEJM199806043382302. PubMed 9614255 ↗
  • Freedman DS. Clustering of coronary heart disease risk factors among obese children. J Pediatr Endocrinol Metab. 2002 Sep-Oct;15(8):1099-108. doi: 10.1515/JPEM.2002.15.8.1099. PubMed 12387507 ↗
  • Aguilar-Salinas CA, Gomez-Perez FJ, Rull J, Villalpando S, Barquera S, Rojas R. Prevalence of dyslipidemias in the Mexican National Health and Nutrition Survey 2006. Salud Publica Mex. 2010;52 Suppl 1:S44-53. doi: 10.1590/s0036-36342010000700008. PubMed 20585729 ↗
  • Corvalan C, Uauy R, Kain J, Martorell R. Obesity indicators and cardiometabolic status in 4-y-old children. Am J Clin Nutr. 2010 Jan;91(1):166-74. doi: 10.3945/ajcn.2009.27547. Epub 2009 Nov 18. PubMed 19923378 ↗
  • Villalpando S, Carrión C, Barquera S, Olaiz G, Robledo R. The body mass index is associated with hyperglycemia and alterations of some components of the metabolic syndrome in Mexican adolescents aged 10-19 years. Salud Pub Mex 2007; 49:s324-s330.
  • Webber LS, Srinivasan SR, Wattigney WA, Berenson GS. Tracking of serum lipids and lipoproteins from childhood to adulthood. The Bogalusa Heart Study. Am J Epidemiol. 1991 May 1;133(9):884-99. doi: 10.1093/oxfordjournals.aje.a115968. PubMed 2028978 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 27, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01178515
Lead sponsor
Instituto Nacional de Salud Publica, Mexico
First posted
Aug 10, 2010
Start date
Sep 2010
Primary completion
Feb 2011
Completion
May 2011
Last update
Jun 27, 2011

Study contacts

Salvador Villalpando, MD, Ph D
principal investigator · Instituto Nacional de Salud Publica, Mexico
Teresa Shamah, M. Sc.
study chair · Instituto Nacional de Salud Publica, Mexico
Yaveth Lara, M Sc
study chair · Instituto Nacional de Salud Publica, Mexico

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion